Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2019-12-16 Proxy Solicitation & In…
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于召开2020年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed notice about convening the 2020 first extraordinary general meeting (临时股东大会) of shareholders for the company 健帆生物科技集团股份有限公司. It includes information about the meeting date, voting procedures (both onsite and online), registration details, agenda items, and proxy forms. There is no financial data or results reported, nor is it a transcript or presentation. It is clearly a formal announcement to shareholders about the meeting and how to participate and vote on proposals. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings. The document length is about 4451 characters, which is consistent with a detailed meeting notice rather than a full report or results announcement.
2019-12-16 Chinese
中航证券有限公司关于公司延长闲置自有资金的现金管理期限的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from the sponsor (中航证券有限公司) regarding the extension of the cash management period for idle proprietary funds of 健帆生物科技集团股份有限公司. It discusses the board and supervisory committee meetings, shareholder approvals, investment purposes, risk analysis, and compliance with regulatory requirements. The document is not a financial report, earnings release, or management discussion but rather a formal verification and opinion related to a specific financing/capital management activity. It is not a simple announcement but a detailed sponsor's verification opinion on a capital management matter. Therefore, the document fits best under Capital/Financing Update (CAP). The document length (6605 characters) and content confirm it is a substantive report, not just an announcement or certification. Hence, the classification is CAP with high confidence.
2019-12-16 Chinese
独立董事关于第三届董事会第四十一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding a specific board meeting matter about extending the cash management period of idle funds. It references regulatory guidelines and company bylaws but does not contain financial statements or detailed financial data. The document is short (529 characters) and focuses on a board-related decision rather than a full report or announcement of voting results. This fits best under Board/Management Information (MANG) as it relates to board opinions on company matters.
2019-12-16 Chinese
第三届董事会第四十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of 健帆生物科技集团股份有限公司 held on December 16, 2019. It details the meeting attendance, the agenda items discussed, and the voting results on specific proposals such as extending the cash management period for idle funds and convening an extraordinary shareholders meeting. The document does not contain financial statements or detailed financial analysis, nor is it a transcript or presentation. It is a formal disclosure of board decisions, which fits the category of Board/Management Information (MANG). The document length is short (1024 characters), and it is not an announcement of a report publication but a direct announcement of board resolutions. Therefore, the classification is MANG with high confidence.
2019-12-16 Chinese
关于延长闲置自有资金现金管理期限的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by a company regarding the extension of the period for cash management of idle funds. It details the board and supervisory committee meetings where the proposal was approved, the need for shareholder approval, investment amounts, types, risk analysis, and opinions from independent directors and the supervisory board. It is not a financial report, earnings release, or management discussion but an official announcement about a corporate financing activity related to cash management of idle funds. The document is over 6,000 characters and contains detailed information about the financing activity but does not contain financial statements or earnings data. Therefore, it fits best under Capital/Financing Update (CAP).
2019-12-16 Chinese
上海荣正投资咨询股份有限公司关于公司2019年第二期股票期权激励计划授予相关事项之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is an Independent Financial Advisor Report related to the 2019 second stock option incentive plan of the company 健帆生物科技集团股份有限公司. It includes detailed explanations of the stock option plan, approval procedures, grant conditions, and the impact on financial results. The document is 9476 characters long, which is substantial and contains detailed financial and procedural information rather than just an announcement. It is not a full annual or quarterly report, nor is it an earnings release or a regulatory filing. It is a specialized report providing an independent financial advisor's opinion on a stock option incentive plan, which is a form of capital/financing update related to stock option grants and equity incentives. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2019-12-05 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.